Stay updated on Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the usual content with an error message and a Home button. This indicates restricted access to the record rather than an update to the trial data.SummaryDifference17%

- Check10 days agoChange DetectedThe page now displays Revision: v3.7.0, replacing Revision: v3.6.6. This indicates a system/template update rather than changes to the study details.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, indicating a small update to the page’s versioning. This change does not alter any study details, eligibility criteria, or other user-visible content.SummaryDifference0.0%

- Check31 days agoChange DetectedA new line '2016 ( U.S. NIH Grant/Contract )' was added to the study's identifiers, signaling an NIH grant/contract reference associated with the trial. This addition expands the funding/administrative attribution attached to the study record.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page's revision label was updated from v3.6.4 to v3.6.5, signaling a new release of the documentation. This likely reflects small corrections or minor updates since the previous version.SummaryDifference0.0%

- Check67 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, indicating a small maintenance update to the page rather than a content change.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.